News Categories

2026 Global Medical Device Regulatory Outlook: ...

Join Us at the 38th European Congress of Pathol...

Naturn Medical Attends 6th Asia Summit on Globa...

Innovative Bone Tissue Processing Solution Shin...

CMEF 2026 Highlights Breakthroughs in Pathology...

Naturn Medical Devices Participated In The 37th...

Hemogenomics Pvt. Ltd. visits Naturn Medical De...

Daffodil Visits Naturn for Collaboration

Naturn Attends Annual Meeting of CPAM Pathology...

Naturn attends 19th CISMEF

2026 Global Medical Device Regulatory Outlook: Navigating New Policies in the US, EU, UK, and Beyond

2026-06-22

Executive Summary

As Chinese medical device manufacturers accelerate their global expansion, the international regulatory landscape is undergoing a profound shift in 2026. Moving beyond traditional market access, new regulations now heavily emphasize AI governance, cybersecurity, data management, and post-market surveillance.

United States: The FDA is deepening AI/ML regulations (focusing on PCCP and cybersecurity) and officially implementing the QMSR, integrating ISO 13485 into US law.
European Union:EUDAMED is entering its mandatory implementation phase, shifting focus to lifecycle data management. Meanwhile, the EU AI Act introduces a "dual regulatory" era for high-risk AI Medical Devices.
United Kingdom: The MHRA proposes indefinite recognition of CE marks and introduces a new regulatory framework featuring international reliance pathways and mandatory UDI.
Canada & Global: Regulatory harmonization for AI is accelerating via Health Canada and the IMDRF, while cybersecurity becomes a universal baseline requirement globally, including in the Middle East.

For Chinese enterprises, building robust algorithm governance, cybersecurity capabilities, and unified quality management systems is no longer optional—it is the fundamental threshold for global success.

Introduction: The New Era of Going Global

In recent years, Chinese medical device companies have rapidly expanded overseas. From medical imaging and in vitro diagnostics (IVD) to surgical robots and AI-driven devices, international markets have become crucial growth engines.

However, going global is not just about market expansion; it requires navigating an ever-evolving international regulatory environment. Entering 2026, the US, EU, UK, Canada, and international regulatory bodies have rolled out multiple reforms. Unlike previous waves that focused primarily on product approval, this new regulatory cycle extends deeply into artificial intelligence governance, cybersecurity, data management, and post-market surveillance. Understanding these shifts is now an indispensable part of any global strategy.

1. United States: Advancing AI Regulation and Quality System Reforms

As the world's largest medical device market, the US remains a top priority for Chinese enterprises.

Deepening AI/ML Medical Device Regulation

The FDA continues to build a robust regulatory framework for AI/Machine Learning-enabled Software as a Medical Device (AI/ML SaMD). By the end of 2025, the FDA had authorized over 1,000 AI-related medical devices, predominantly in radiology and medical imaging.

Key Requirements: The FDA focuses heavily on the Predetermined Change Control Plan (PCCP), continuous learning algorithm management, and post-market performance monitoring. Companies must prove not only initial safety and efficacy but also establish a lifecycle algorithm management system ensuring that model updates are traceable, verifiable, and controllable.
Cybersecurity Integration: Following the 2023 final guidance on cybersecurity, the FDA now mandates that companies establish security management systems covering design, development, and maintenance. Submissions must include a Software Bill of Materials (SBOM), vulnerability management plans, and risk control documents.
Impact: Competition in the US market has shifted from mere product performance to software development, data governance, and cybersecurity capabilities. Furthermore, enhanced FDA-MHRA collaboration on AI regulation may increase compliance costs and extend approval timelines for companies targeting both markets.

QMSR Takes Effect: A New Era for US Quality Systems

On February 2, 2026, the FDA’s Quality Management System Regulation (QMSR) officially took effect, retiring the 30-year-old 21 CFR Part 820.

Key Requirements: QMSR incorporates ISO 13485:2016 by reference, making it a legal baseline rather than just a "bonus." However, the FDA retains specific requirements for record-keeping, labeling, UDI, and Medical Device Reporting (MDR) that are not covered by ISO. Additionally, the FDA released a new inspection compliance manual in January 2026, shifting the inspection logic from "checking documents" to "auditing the entire chain and emphasizing data."
Impact: While QMSR reduces the operational costs of maintaining dual systems (FDA QSR and ISO 13485), the bar for compliance is higher. An ISO certificate does not equal FDA compliance; companies must still pass rigorous FDA on-site inspections and reconstruct their documentation systems to embed risk management throughout the product lifecycle.

2. European Union: EUDAMED Acceleration and the AI Act

In 2026, the EU's regulatory focus is shifting from MDR/IVDR certification to dynamic, lifecycle-wide data management.

EUDAMED Enters Mandatory Implementation

The European Database on Medical Devices (EUDAMED) is transitioning into its mandatory phase. Starting May 28, 2026, core modules—including economic operator registration, UDI/device registration, notified bodies, and market surveillance—will be strictly enforced.

Key Requirements: Companies must complete entity registration, product data maintenance, and UDI updates according to the timeline. Failure to comply will result in market access denial.
1. Data Overload: Companies with extensive product lines face massive workloads to translate and verify dozens of data fields per UDI-DI.
2. System Upgrades: ERP and PLM systems must be upgraded to support UDI generation and EUDAMED integration.
3. Cross-Departmental Collaboration: UDI compliance now requires seamless coordination across R&D, production, quality, logistics, IT, and supply chain partners.

The AI Act Ushers in a "Dual Regulatory Era"

The EU AI Act (Regulation (EU) 2024/1689) is now law. AI systems used in medical devices are classified as high-risk.

Key Requirements: By August 2, 2027, AI medical technologies already regulated under MDR/IVDR must also comply with the AI Act. This includes stringent requirements for risk management, transparency, data governance, cybersecurity, and human oversight.
Impact: Companies must integrate AI-specific regulatory requirements into the R&D phase alongside traditional MDR/IVDR standards to minimize certification delays and compliance costs.

3. United Kingdom: An Independent Regulatory Framework Takes Shape

Post-Brexit, the UK’s MHRA is actively restructuring its medical device regulations.

Indefinite Recognition of CE Marks Proposed

In February 2026, the MHRA proposed the indefinite recognition of CE-marked devices in Great Britain, aligning the acceptance period with the EU's MDR/IVDR transition deadlines (up to Dec 31, 2028).

Impact: This significantly reduces the urgency for UKCA marking. Companies, especially SMEs, can continue relying on CE certification, avoiding duplicate testing and costs. Resources can be redirected to higher-priority compliance tasks like EU MDR and the AI Act. However, new registration fees and mandatory checks post-April 1, 2026, require swift budget and operational adjustments.

New Medical Devices Regulations Draft

In May 2026, the MHRA released a revised draft regulation to comprehensively update the GB market framework.

Key Requirements: The update introduces an international reliance pathway (allowing faster market entry for devices approved in the US, Canada, or Australia starting in 2028), mandatory UDI, refined classification rules, specific controls for software devices, and the introduction of PCCP mechanisms.
Impact: The PCCP mechanism is highly beneficial for AI device manufacturers. While international reliance will shorten time-to-market for globally approved devices, mandatory UDI and technical documentation upgrades will increase short-term compliance investments.

4. Canada & Global Organizations: Harmonizing AI Frameworks

Canada Advances ML Device Regulation

Health Canada is building a regulatory framework for Machine Learning-enabled devices that closely mirrors the FDA. Focus areas include PCCP, data quality, bias control, and lifecycle management. Establishing a unified AI governance system will help companies lower compliance costs across the North American market.

IMDRF Drives Global AI Harmonization

The International Medical Device Regulators Forum (IMDRF) is actively developing technical documents on AI lifecycle management, focusing on risk management, model updates, and post-market surveillance. Aligning product development with IMDRF frameworks will significantly boost global market access efficiency.

Middle East Strengthens Cybersecurity Rules

Markets like Saudi Arabia are increasingly mandating cybersecurity requirements for digital health products. Submissions now routinely require an SBOM, vulnerability management plans, and cybersecurity risk controls. Cybersecurity is rapidly becoming a universal baseline for global market entry.